Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation

(2009) A. N. Stratman et al.   BLOOD

Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices

(2009) A. N. Stratman et al.   BLOOD

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

(2009) David A. Reardon et al.   CANCER

Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

(2009) Zhizhong Li et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

(2009) Mark P. Saunders et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

(2009) C. Folkins et al.   CANCER RESEARCH

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating endothelial progenitor cells in malignant gliomas

(2009) Neysan Rafat et al.   JOURNAL OF NEUROSURGERY

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

(2009) L. G. Daenen et al.   MOLECULAR CANCER THERAPEUTICS

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells

(2008) F. Shojaei et al.   CANCER RESEARCH

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study

(2008) A. Dowlati et al.   CLINICAL CANCER RESEARCH

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

(2008) H. J. Burstein et al.   CLINICAL CANCER RESEARCH

Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy

(2008) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse

(2008) N. Giri et al.   DRUG METABOLISM AND DISPOSITION

A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2008) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer

(2008) Fabio Efficace et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

(2008) Tyler Y. Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

(2008) Vinay K. Puduvalli et al.   NEURO-ONCOLOGY

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

(2008) David A. Reardon et al.   NEURO-ONCOLOGY

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas

(2008) R. S. Kerbel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef

(2008) S. Guiu et al.   REVUE NEUROLOGIQUE